MARKET

OPK

OPK

OPKO Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.550
+0.030
+0.66%
After Hours: 4.540 -0.01 -0.22% 19:58 01/15 EST
OPEN
4.620
PREV CLOSE
4.520
HIGH
4.780
LOW
4.540
VOLUME
6.31M
TURNOVER
--
52 WEEK HIGH
6.47
52 WEEK LOW
1.117
MARKET CAP
3.05B
P/E (TTM)
-24.8498
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
OPKO Health's (OPK) BioReference Extends Digital Health Access
OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.
Zacks · 1d ago
Opko Health expects to beat its guidance for PCR tests for Covid in 4Q
Opko Health (OPK) expects to beat its previously issued guidance for PCR tests for Covid-19 for 4Q and confirmed its revenue guidance, CFO Adam Logal said earlier at the JPMorgan
Seekingalpha · 2d ago
OPKO Health's subsidiary introduces Scarlet Health in-home diagnostic service
OPKO Health (OPK) company BioReference Laboratories announces introduction of Scarlet Health, an in-home, fully integrated digital platform providing access to on-demand diagnostic services."Scarlet is the first of many digital health advances at BioReference that aim to increase flexibility and convenience for patients," Richard Schwabacher
Seekingalpha · 2d ago
OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access
, /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced , an in-home, fully integrated digital platform providing access to on-demand diagnostic services. Scarlet has been designed similarly to tools consumers use daily, in order to provide ease-of-use and ubiquitous conveniences. 
PR Newswire - PRF · 2d ago
OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic services. Scarlet has been designed similarly to tools consumers use daily, in order to provide ease-of-use and ubiquitous conveniences.
PR Newswire · 2d ago
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance
Sian Capital, a sizable stockholder of OPKO Health (OPK) disagrees with the 4Q20 guidance issued by the management on October 29, 2020.Sian Capital affirms its Q4 estimate as it correctly
Seekingalpha · 2d ago
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q'20 Guidance
Sian Capital, LLC (together with its affiliates, "Sian" or "we"), a sizable stockholder of OPKO Health, Inc. (NASDAQ: OPK) ("OPKO" or the "Company"), today announced that it sent a letter to the Company's Board of Directors (the "Board") on December 18, 2020 regarding what we believe is the dubious 4Q'20 guidance provided by management on October 29, 2020. Sian wants all analysts and stockholders to be aware that we believe OPKO's previously issued guidance is misleading. We are calling on OPKO to confirm whether it still stands by its projections or agrees with our estimates.
GlobeNewswire · 3d ago
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance
Calls on Analysts and Stockholders Attending J.P. Morgan’s Healthcare Conference to Determine Whether Management Disputes our Analysis and Stands by Original 4Q’20 GuidanceNEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sian Capital, LLC (together with its affiliates, “Sian” or “we”), a sizable stockholder of OPKO Health, Inc. (NASDAQ: OPK) (“OPKO” or the “Company”), today announced that it sent a letter to the Company’s Board of Directors (the “Board”) on December 18, 2020 regarding what we believe is the dubious 4Q’20 guidance provided by management on October 29, 2020. Sian wants all analysts and stockholders to be aware that we believe OPKO’s previously issued guidance is misleading. We are calling on OPKO to confirm whether it still stands by its projections or agrees with our estimates. Please be advised that OPKO’s management will be hosting one-on-one meetings with investors and presenting at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 3:40 p.m. Eastern. We encourage analysts and investors to review our estimates against OPKO’s guidance and ask management whether it stands by the Company’s 4Q’20 guidance. Given that we believe Sian correctly predicted OPKO’s 3Q’20 financial results before they were announced, we remain very confident that our current analysis of OPKO’s 4Q’20 financials is accurate.The below table outlines guidance OPKO provided on its October 29, 2020 conference call compared to the conservative guidance estimates Sian released on November 12, 2020. Our analysis leads us to believe that OPKO under-guided 4Q’20 growth by 26.3%. EBITDASerology Tests PCR TestsCOVID-19 Tests* OPKO 4Q’20 Guidance$20-30 million300,0002.9-3.5 million3.2-3.8 million Sian's Estimate$30-40 million300,0003.9-4.5 million4.2-4.8 million *OPKO's "COVID-19 testing guide" includes Serology and PCR Tests.The day after OPKO announced its projections, the stock price dropped 20%. In stark contrast, OPKO’s stock price increased 25% in the weeks after we released our 4Q’20 estimates on November 12, 2020.In our White Paper on OPKO’s fundamental value, we refute OPKO’s guidance in detail and provide, in our view, a more accurate guide using public data, the Company’s commentary, public competitors, competitors in the supply chain, government statistics and independent market analysis. We view OPKO’s 4Q’20 guidance as unfathomable and urge analysts and investors to ask management today whether the Company: 1. Disagrees with our analysis and stands by its original 4Q’20 guidance, or 2. Agrees with our analysis and admits its original 4Q’20 guidance was incorrect. In closing, Sian remains open and willing to engage with OPKO regarding its ideas for high-potential opportunities in the marketplace. Unfortunately, it seems management is no longer interested in engaging with us after ignoring our latest attempts to try to work collaboratively to drive stockholder value. We find it troubling that management would seemingly rather spend investor resources fighting one of its largest stockholders instead of resuming productive discussions with us.For those interested in learning more about the value opportunity at OPKO, visit www.SianCapital.com/Resources. We have provided Sian’s projected 2021 guidance for the Company. Despite recent events, we remain encouraged by the numerous growth prospects for OPKO and its stockholders in 2021.About Sian CapitalFounded by veteran portfolio manager Anish Monga, Sian Capital, LLC is a New York-based asset management firm that employs a focused, event-driven investment approach. Sian’s unique mix of cross-sector experience and activism expertise enables it to identify and invest in what are often overlooked or under-covered investment opportunities.ContactsProfile Greg Marose / Charlotte Kiaie gmarose@profileadvisors.com / ckiaie@profileadvisors.com
GlobeNewswire · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPK. Analyze the recent business situations of OPKO Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPK stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 337
Institutional Holdings: 204.07M
% Owned: 30.46%
Shares Outstanding: 670.00M
TypeInstitutionsShares
Increased
71
16.07M
New
67
653.82K
Decreased
61
20.78M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.43%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Chief Executive Officer/Director
Phillip Frost
Vice Chairman/Chief Technology Officer/Director
Jane Hsiao
Chief Financial Officer/Senior Vice President/Chief Accounting Officer/Treasurer
Adam Logal
Corporate Executive/Director
Jon Cohen
Senior Vice President
Akhtar Ashfaq
Corporate Executive
Charles Bishop
Other
Thomas Nusbickel
Corporate Executive
Tony Cruz
Corporate Executive
Geoff Monk
Executive Vice President/Director
Steven Rubin
Independent Director
Robert Fishel
Independent Director
Anthony Japour
Independent Director
Richard Krasno
Independent Director
Richard Lerner
Independent Director
Roger Medel
Independent Director
John Paganelli
Independent Director
Richard Pfenniger
Independent Director
Alice Yu
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.